Work

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz244.013

Authors: A. Stradella, M.L. Johnson, S. Goel, S.R. Chandana, M.D. Galsky, E. Calvo, V. Moreno, H. Park, H.-T. Arkenau, A. Cervantes, L Fariñas Madrid, L. Mileshkin, R. Plummer, J. Evans, L. Horvath, A. Prawira, R.J. Pelham, S. Mu, C. Andreu-Vieyra, M. Barve

Institutions: Institut Català d'Oncologia, Sarah Cannon, Albert Einstein College of Medicine, Montefiore Medical Center, Start Treatment & Recovery Centers, Icahn School of Medicine at Mount Sinai, Hospital Universitario Fundación Jiménez Díaz, Washington University in St. Louis, Sarah Cannon Research Institute, Universitat de València, Peter MacCallum Cancer Centre, Newcastle University, Beatson West of Scotland Cancer Centre, Chris O’Brien Lifehouse, St Vincent's Hospital Sydney, Mary Crowley Cancer Research Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977332918

FWCI: 0.105

Cites:

Cited by: 1

Related to: 10